SOX方案对比CapeOX方案治疗转移性结直肠癌的成本—效果分析(4)
[ 6 ] HONG YS， PARK YS， LIM HY， et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer： a randomised， non-inferiority phase 3 trial[J]. Lancet Oncol， 2012，13(11)：1125-1132.
[ 7 ] GRAHAM CN，MAGLINTE GA，SCHWARTZBERG LS， et al. Economic analysis of panitumumab compared with cetuximab in patients with wild-type KRAS metastatic colorectal cancer that progressed after standard chemotherapy[J]. Clin Ther，2016，38(6)：1376-1391.
[ 8 ] PETROU PK，TALIAS MA.Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus[J]. Expert Rev Pharmacoecon Outcomes Res，2014，14(1)：131-138.
[ 9 ] PURMONEN T， MARTIKAINEN JA， SOINI EJ， et al. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland[J]. Clin Ther，2008，30(2)：382-392.
[10] EICHLER HG， KONG SX， GERTH WC， et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making： how are cost-effectiveness thresholds expected to emerge？ [J] Value Health， 2004，7(5)：518-528.
[11] Wikipedia. List of Chinese administrative divisions by GDP per capita[EB/OL].[2016-12-01].https：//en.wikipedia.org/wiki/List_of_Chinese_administrative_divisions_by_ GDP_ per_capita.
[12] China Foreign Exchange Trade System (CFETS). CNY central historical parity rate[EB/OL].[2016-12-01].http：//www.chinamoney.com.cn/english/bmkcpr/index.html？tab=2.
(收稿日期：2017-04-09 修回日期：2018-02-03)
(編辑：周 箐), 百拇医药(秦舟 占美 何治尧 徐珽)
[ 7 ] GRAHAM CN，MAGLINTE GA，SCHWARTZBERG LS， et al. Economic analysis of panitumumab compared with cetuximab in patients with wild-type KRAS metastatic colorectal cancer that progressed after standard chemotherapy[J]. Clin Ther，2016，38(6)：1376-1391.
[ 8 ] PETROU PK，TALIAS MA.Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus[J]. Expert Rev Pharmacoecon Outcomes Res，2014，14(1)：131-138.
[ 9 ] PURMONEN T， MARTIKAINEN JA， SOINI EJ， et al. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland[J]. Clin Ther，2008，30(2)：382-392.
[10] EICHLER HG， KONG SX， GERTH WC， et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making： how are cost-effectiveness thresholds expected to emerge？ [J] Value Health， 2004，7(5)：518-528.
[11] Wikipedia. List of Chinese administrative divisions by GDP per capita[EB/OL].[2016-12-01].https：//en.wikipedia.org/wiki/List_of_Chinese_administrative_divisions_by_ GDP_ per_capita.
[12] China Foreign Exchange Trade System (CFETS). CNY central historical parity rate[EB/OL].[2016-12-01].http：//www.chinamoney.com.cn/english/bmkcpr/index.html？tab=2.
(收稿日期：2017-04-09 修回日期：2018-02-03)
(編辑：周 箐), 百拇医药(秦舟 占美 何治尧 徐珽)